<DOC>
	<DOCNO>NCT00800202</DOCNO>
	<brief_summary>This study ass efficacy safety Avastin combine first li ne paclitaxel-carboplatin ( cohort 1 ) second line Tarceva ( cohort 2 ) patien ts non-squamous non-small cell lung cancer asymptomatic untreated brai n metastasis . Two cohort patient study ; first receive Av astin 15mg/kg iv every 3 week combine first line paclitaxel 200mg/m2 iv p lu carboplatin AUC6 iv every 3 week maximum 6 cycle , second cohort receive Avastin 15mg/kg iv every 3 week combine second line T arceva 150mg/kg po.The anticipated time study treatment disease prog ression , target sample size 100-500 individual .</brief_summary>
	<brief_title>A Study Avastin ( Bevacizumab ) Patients With Non-Squamous Non-Small Cell Lung Cancer With Asymptomatic Untreated Brain Metastasis</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>adult patient , &gt; =18 year age ; stage IV nonsquamous nonsmall cell lung cancer ; asymptomatic , untreated brain metastasis ; ECOG performance status 01. previous treatment brain metastasis ; history migraine epilepsy ; previous treatment angiogenesis inhibitor ; cohort 2 , previous first line treatment Avastin Tarceva ; current recent use aspirin ( &gt; 325mg/day ) fulldose anticoagulant thrombolytic agent therapeutic purpose .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>